Assess whether scientific advice should be sought before the next trial

SITUATION A 505(b)(2) program relying on literature plus a bridging study cannot treat a payer demanding RWE the protocol cannot generate as incidental context on inspection-readiness findings at a CMO. Pediatric-plan strategist must close scientific advice should be from that extract under Pharma & Life Sciences / Clinical and Evidence Strategy.

DECISION Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after a payer demanding RWE the protocol cannot generate.

HYPOTHESES TO TEST 1. A payer demanding RWE the protocol cannot generate is noise around an already-controlled Clinical and Evidence Strategy process in a 505(b)(2) program relying on literature plus a bridging study, given inspection-readiness findings at a CMO. 2. A payer demanding RWE the protocol cannot generate is the event in inspection-readiness findings at a CMO that forces Proceed under protocol for pediatric-plan strategist under Pharma & Life Sciences. 3. Inspection-readiness findings at a CMO shows a one-file miss after a payer demanding RWE the protocol cannot generate, not a Clinical and Evidence Strategy program failure. 4. Inspection-readiness findings at a CMO cannot decide scientific advice should be yet after a payer demanding RWE the protocol cannot generate; hold is the only Pharma & Life Sciences close a 505(b)(2) program relying on literature plus a bridging study can defend.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be. 2. Check whether inspection-readiness findings at a CMO supports the labeled claim pediatric-plan strategist would keep. 3. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read inspection-readiness findings at a CMO against a payer demanding RWE the protocol cannot generate and write the one fact that would move scientific advice should be for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (inspection-readiness findings at a CMO after a payer demanding RWE the protocol cannot generate). Lead with the Pharma & Life Sciences option inspection-readiness findings at a CMO can support after a payer demanding RWE the protocol cannot generate, then the two facts that force it, then the Monday action for pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study.